The process of engaging members from two underserved populations in the development of interventions to promote the uptake of the HPV vaccine.

Mira L Katz, Electra D Paskett
Author Information
  1. Mira L Katz: The Ohio State University, Columbus, OH, USA mira.katz@osumc.edu.
  2. Electra D Paskett: The Ohio State University, Columbus, OH, USA.

Abstract

We describe a community-engaged research process used to develop multilevel interventions (caregivers, providers, system) to improve the uptake of human papillomavirus vaccine among adolescents by partnering with members from two underserved populations in Ohio. We began by conducting focus groups to better understand the knowledge and attitudes of caregivers and providers about the human papillomavirus vaccine and to develop teams of community members to assist with development of the interventions. The process continued with conducting writing sessions to determine the content and format of the interventions, and initial feedback was obtained during review sessions to refine the interventions prior to implementation. Using this approach, we were able to consider contextual factors that made the interventions more acceptable and relevant to members of the priority populations. Challenges included development and maintenance of a team of community members to participate in the entire intervention development process, rejection of ideas presented by academic researchers, the need to balance community members' suggestions with what was known from evidence-based research, and the time, cost, and effort associated with partnering with community members. The benefits, however, outweigh the challenges associated with using a community-engaged research process to develop interventions aimed at reducing cancer disparities among underserved populations.

Keywords

References

  1. Health Promot Pract. 2013 Jul;14(4):624-36 [PMID: 23099659]
  2. J Infect Dis. 2011 Aug 15;204(4):566-73 [PMID: 21791659]
  3. J Rural Health. 2005 Spring;21(2):149-57 [PMID: 15859052]
  4. Pediatrics. 2013 Jun;131(6):1114-24 [PMID: 23650297]
  5. J Cancer Educ. 2013 Dec;28(4):784-9 [PMID: 23857185]
  6. Am J Public Health. 2009 Dec;99(12):2176-8 [PMID: 19833982]
  7. Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2354-61 [PMID: 21949110]
  8. Vaccine. 2012 Jul 13;30(33):4960-3 [PMID: 22652406]
  9. Prev Chronic Dis. 2012;9:110344 [PMID: 22863307]
  10. Sex Transm Dis. 2013 Jul;40(7):534-8 [PMID: 23965766]
  11. Vaccine. 2014 Jan 23;32(5):579-84 [PMID: 24315883]
  12. Am J Mens Health. 2014 Mar;8(2):167-74 [PMID: 24085197]
  13. MMWR Morb Mortal Wkly Rep. 2002 Jun 21;51(24):527-9 [PMID: 12088143]
  14. J Pediatr Health Care. 2014 Mar-Apr;28(2):155-64 [PMID: 23522561]
  15. Health Soc Work. 2010 Nov;35(4):302-9 [PMID: 21171537]
  16. Infect Dis Clin North Am. 2013 Dec;27(4):765-78 [PMID: 24275269]
  17. Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):6-10 [PMID: 14982671]
  18. Prev Chronic Dis. 2006 Oct;3(4):A127 [PMID: 16978502]
  19. JAMA. 2012 Feb 15;307(7):693-703 [PMID: 22282321]
  20. Health Educ Behav. 2007 Jun;34(3):471-85 [PMID: 17000622]
  21. J Urban Health. 2005 Jun;82(2 Suppl 2):ii3-12 [PMID: 15888635]
  22. Clin Obstet Gynecol. 2013 Mar;56(1):65-75 [PMID: 23314716]
  23. Hum Vaccin Immunother. 2013 Jan;9(1):90-6 [PMID: 23143774]
  24. Vaccine. 2013 Dec 31;31 Suppl 7:H1-31 [PMID: 24332295]
  25. J Infect Dis. 2009 Mar 15;199(6):805-14 [PMID: 19199546]
  26. Vaccine. 2014 Apr 7;32(17):1901-20 [PMID: 24530401]
  27. Sex Transm Dis. 2011 Oct;38(10):932-40 [PMID: 21934568]
  28. J Natl Cancer Inst Monogr. 2012 May;2012(44):11-9 [PMID: 22623591]
  29. Environ Health Perspect. 2005 Oct;113(10):1463-71 [PMID: 16203263]
  30. MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30 [PMID: 25167164]
  31. J Am Coll Health. 2014;62(1):32-8 [PMID: 24313694]
  32. J Commun. 2013 Feb;63(1):95-115 [PMID: 26560123]
  33. Vaccine. 2009 Jun 19;27(30):3945-52 [PMID: 19389447]
  34. Am J Public Health. 2010 Nov;100(11):2094-102 [PMID: 20864728]
  35. Cancer. 2008 Jan 1;112(1):181-92 [PMID: 18000806]
  36. Cancer Epidemiol Biomarkers Prev. 2012 Dec;21(12):2220-30 [PMID: 23136141]
  37. Patient Educ Couns. 2000 Sep;41(2):209-22 [PMID: 12024545]

Grants

  1. R21 CA152803/NCI NIH HHS
  2. P50 CA105632/NCI NIH HHS
  3. P50CA105632/NCI NIH HHS
  4. R21CA152803/NCI NIH HHS
  5. P30CA016058/NCI NIH HHS
  6. P30 CA016058/NCI NIH HHS

MeSH Term

Adolescent
Appalachian Region
Female
Focus Groups
Health Knowledge, Attitudes, Practice
Health Promotion
Humans
Male
Ohio
Papillomavirus Infections
Papillomavirus Vaccines
Parents
Patient Acceptance of Health Care
Urban Population
Uterine Cervical Neoplasms
Vulnerable Populations

Chemicals

Papillomavirus Vaccines

Word Cloud

Created with Highcharts 10.0.0interventionsmembersprocessresearchvaccinepopulationscommunitydevelopmentcommunity-engageddevelopunderservedcaregiversprovidersuptakehumanpapillomavirusamongpartneringtwoconductingsessionsassociatedcancerdisparitiesHPVdescribeusedmultilevelsystemimproveadolescentsOhiobeganfocusgroupsbetterunderstandknowledgeattitudesteamsassistcontinuedwritingdeterminecontentformatinitialfeedbackobtainedreviewrefinepriorimplementationUsingapproachableconsidercontextualfactorsmadeacceptablerelevantpriorityChallengesincludedmaintenanceteamparticipateentireinterventionrejectionideaspresentedacademicresearchersneedbalancemembers'suggestionsknownevidence-basedtimecosteffortbenefitshoweveroutweighchallengesusingaimedreducingengagingpromotecervicalhealth

Similar Articles

Cited By